Innoviva, Inc. (Nasdaq: INVA) Files 10-K/A – Key Details for Investors

Summary of Filing

Innoviva, Inc. has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The filing, dated March 27, 2026, primarily serves to provide new certifications from the Principal Executive Officer and Principal Financial Officer and to incorporate specific documents by reference. Importantly, this amendment does not reflect any events after the original filing date and does not update prior disclosures except as described in the explanatory note.

Key Points Shareholders Should Know

• Amendment Filing: The 10-K/A is an amendment to the original annual report (10-K). It includes new certifications from company officers as required by SEC rules, but does not change financial results or other disclosures from the original filing.
• Market Value & Share Count:
  • The aggregate market value of voting and non-voting common equity held by non-affiliates was \$1.26 billion as of June 30, 2025.
  • As of February 13, 2026, there were 77,646,000 shares of common stock outstanding.
• Exchange and Trading Symbol: The company’s common stock trades on the Nasdaq Stock Market LLC under the symbol INVA.
• Well-Known Seasoned Issuer: Innoviva is a “well-known seasoned issuer” under SEC rules, meaning it has broad access to capital markets and is subject to enhanced reporting requirements.
• Internal Controls: The filing confirms that Deloitte & Touche LLP, the independent auditor, has attested to the effectiveness of Innoviva’s internal controls over financial reporting under Section 404(b) of the Sarbanes-Oxley Act.
• No Error Corrections or Restatements: The amendment confirms there were no corrections of errors or restatements requiring recovery analysis of incentive-based compensation for executive officers.
• Not a Shell Company: Innoviva is not classified as a shell company.
• Financial Statement Details:
  • Financial statements, including consolidated balance sheets, statements of income and comprehensive income, stockholders’ equity, and cash flows for 2023-2025, are incorporated by reference from the original filing.
  • Audit by Deloitte & Touche LLP (PCAOB Firm ID 34).
  • All financial statement schedules have been omitted as either not required or provided elsewhere.
• Documents Incorporated by Reference:
  • Portions of the definitive Proxy Statement for the 2026 Annual Meeting of Stockholders will be incorporated into Part III of the Annual Report, expected to be filed within 120 days of fiscal year-end.
• Exhibit Index: The filing includes an extensive list of material contracts, investor agreements, equity plans, insider trading policies, clawback policy (effective October 2, 2023), and audited financial statements of subsidiaries such as Armata Pharmaceuticals, Inc. Notable exhibits include:
  • Amended and Restated Certificate of Incorporation
  • Amended and Restated Bylaws
  • Convertible Subordinated Note Forms
  • Investor Rights Agreements
  • Equity Incentive Plans (including 2023 Employee Stock Purchase Plan)
  • Insider Trading Policy and Clawback Policy
  • List of subsidiaries
  • Auditor consents and certifications

Potentially Price-Sensitive Information

There is no new financial information, guidance, or operational update disclosed in this amendment that would directly affect share value. The amendment is procedural, primarily to provide updated certifications and to incorporate previously referenced documents. There are no corrections, restatements, or new disclosures that would impact investor perception or share price.

Important Reminders for Shareholders

• No change to previously reported financials or business outlook. Investors should rely on the original 10-K and subsequent SEC filings for financial and operational developments.
• Certifications strengthen compliance posture. The updated officer certifications reaffirm Innoviva’s compliance with SEC regulations.
• Clawback Policy in Effect. The recently adopted clawback policy (effective October 2, 2023) is relevant for executive compensation and governance.
• Proxy Statement Incorporation. Further governance and executive compensation details may be provided in the upcoming Proxy Statement.

Conclusion

Bottom Line for Investors: The 10-K/A amendment does not contain new financial results, business developments, or events likely to move the share price. It is primarily a compliance update. Investors should monitor the upcoming Proxy Statement and other SEC filings for any substantive news or disclosures.

Disclaimer: This article is based on Innoviva, Inc.’s SEC filing (10-K/A) for informational purposes only. It does not constitute investment advice. Investors are advised to review the full filing and consult with their financial advisors before making any investment decisions. No new material events have been disclosed in this amendment.

View Innoviva, Inc. Historical chart here